Aviceda Therapeutics: Funding, Investors & Team (Sep 2026)
Aviceda Therapeutics is a biotech company in the late stages of pre-clinical development that is focused on creating drugs to treat glyco-immune diseases. Their approach involves utilizing the field of glycobiology to target the innate immune system and chronic inflammation in a precise and powerful manner. They leverage advanced technologies and in-depth biological understanding to develop innovative products. Aviceda's high-throughput screening platform is used to quickly identify and refine ligands with high affinity and specificity for various types of innate immune cells. The company's product pipeline includes treatments for eye diseases, fibrosis, neurology, and oncology, such as AVD-104, AVD-302, and AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma, as well as AVD-601, AVD-701, and AVD-801 for oncology, neurology, and fibrosis.
Aviceda Therapeutics has raised $223M across 2 funding rounds on record, the most recent a Series C of $208M announced in Jan 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aviceda Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2025.
Aviceda Therapeutics Funding Rounds
Aviceda Therapeutics raised $15.6M in an undisclosed round announced in May 2023.
1.7 years later, a Series C of $208M was announced in Jan 2025.
Aviceda Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Aviceda Therapeutics Funding Compared to Other Biotechnology Startups
Aviceda Therapeutics' latest round of $208M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aviceda Therapeutics in Biotechnology and Cambridge
Companies Similar to Aviceda Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Aviceda Therapeutics Funding FAQs
What does Aviceda Therapeutics do?
Aviceda Therapeutics is a biotech company in the late stages of pre-clinical development that is focused on creating drugs to treat glyco-immune diseases. Their approach involves utilizing the field of glycobiology to target the innate immune system and chronic inflammation in a precise and powerful manner. They leverage advanced technologies and in-depth biological understanding to develop innovative products. Aviceda's high-throughput screening platform is used to quickly identify and refine ligands with high affinity and specificity for various types of innate immune cells. The company's product pipeline includes treatments for eye diseases, fibrosis, neurology, and oncology, such as AVD-104, AVD-302, and AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma, as well as AVD-601, AVD-701, and AVD-801 for oncology, neurology, and fibrosis.
How much funding has Aviceda Therapeutics raised?
Aviceda Therapeutics has raised $223M across 2 rounds on record. The most recent is a Series C of $208M announced in Jan 2025.
When did Aviceda Therapeutics last raise funding?
Aviceda Therapeutics' most recent funding round on record is a Series C of $208M, announced in Jan 2025.
Who founded Aviceda Therapeutics?
FundedIQ lists Christopher Scott (Founder), Michael Tolentino (Founder) at Aviceda Therapeutics.
Where is Aviceda Therapeutics headquartered?
Aviceda Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Aviceda Therapeutics have?
Aviceda Therapeutics is in the 51-100 employee band.
How does Aviceda Therapeutics' funding compare to other Biotechnology startups?
Aviceda Therapeutics' latest round of $208M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Aviceda Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aviceda Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.